Results 161 to 170 of about 134,704 (353)

The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.
Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley   +1 more source

BMP-7 Protein Expression Is Downregulated in Human Diabetic Nephropathy

open access: yesActa Clinica Croatica, 2015
Bone morphogenetic protein-7 (BMP-7) is expressed in all parts of the normal kidney parenchyma, being highest in the epithelium of proximal tubules. It protects kidney against acute and chronic injury, inflammation and fibrosis.
Renata Ivanac-Janković   +5 more
doaj  

Metabolic abnormalities and reprogramming in cats with naturally occurring hypertrophic cardiomyopathy

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1256-1270, April 2025.
Abstract Background and aims The heart is a metabolic organ rich in mitochondria. The failing heart reprograms to utilize different energy substrates, which increase its oxygen consumption. These adaptive changes contribute to increased oxidative stress.
Qinghong Li   +12 more
wiley   +1 more source

Pulmonary congestion relief by adding dapagliflozin to intravenous loop diuretic in acute heart failure patients

open access: yesESC Heart Failure, EarlyView.
Abstract Aims We aim to assess the efficacy of congestion relief and safety associated with adding SGLT2i (viz., dapagliflozin 10 mg) to intravenous loop diuretics within 24 h of hospital presentation in patients with acute heart failure (AHF). Methods and results A single‐centre open‐label clinical research study enrolled 98 patients admitted with an ...
Daniela Mocan   +7 more
wiley   +1 more source

Structural requirements for protection by small amino acids against hypoxic injury in kidney proximal tubules 1 [PDF]

open access: green, 1990
Joel M. Weinberg   +4 more
openalex   +1 more source

Initial clinical experience with dapagliflozin in addition to optimized medical therapy in paediatric heart failure patients

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Dapagliflozin, a sodium‐glucose cotransporter 2 (SGLT2) inhibitor, has shown clinical benefits in adults with heart failure (HF), improving cardiac function, reducing HF‐related hospitalizations and enhancing survival rates. While extensively studied in adult HF, data on its efficacy and safety in paediatric HF patients remain limited. We
Lisa‐Maria Rosenthal   +5 more
wiley   +1 more source

Association of baseline and longitudinal changes in insulin‐like growth factor‐binding protein‐7 with the risk of incident heart failure: Data from the PREVEND study

open access: yesEuropean Journal of Heart Failure, EarlyView.
Insulin‐like growth factor‐binding protein‐7 (IGFBP7) and heart failure (HF) risk: the PREVEND study. CI, confidence interval; HR, hazard ratio. Abstract Aim Senescence is a major risk factor for heart failure (HF), and insulin‐like growth factor‐binding protein‐7 (IGFBP7) has been identified as an important senescence‐inducing factor.
Sabrina Abou Kamar   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy